Get Unlimited Plan at 75% OFF!

Advertisement
logo

Concord Biotech

CONCORDBIO
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Concord Biotech Share price and Fundamental Analysis

View All Details
View All Details
Concord Biotech Ltd was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC.
Company Incorporation1984
ChairmanNA
Head QuartersAhmedabad
Previous NameNA

Key Metrics

Market Cap (Cr)
14,538
PE Ratio
44.56
Industry P/E
35.07
PEG Ratio
6.26
ROE
20.62%
ROCE
27.79%
ROA
18.49%
Total Debt (Cr)
3.43
Debt to Equity
0
Dividend Yield
0.63%
EPS
31.19
Book Value & P/B
152.02 x 9.14
Face Value
1
Outstanding Shares(Cr)
10.46
Current Ratio
6.68
EV to Sales
13.34

Included In

+More

Stock Returns

1 Week-8.03%
1 Month-12.52%
6 Months-24.51%
1 Year-6.97%
3 Years+48.13%
5 Years+48.13%

CAGR

1 Year CAGR

Revenue Growth

N/A

Net Profit Growth

N/A

Operating Profit Growth

N/A

Dividend Growth

+28.11%

Stock Returns CAGR

-6.97%
no_data

No Stocks

Smart Score

1.9
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 44.08%

FIIs : 9.35%

DIIs : 9.16%

Public : 37.41%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
FII Shareholding Increased by 1.02% to 9.35% in March 2025 Qtr
DII Shareholding Decreased by 0.5% to 9.16% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Concord Biotech Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Concord Biotech Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Concord Biotech Ltd was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC.

The Company is an India-based biopharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immuno-suppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat.

In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid.

In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat. It set up a joint venture in Japan to grow business in 2018.

In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg.

In 2020, Mycophenolate Sodium Tablets got launched in the US market.

A second API manufacturing facility at Limbasi was launched, which commenced operations in July, 2021.

As of March 31, 2022, the Company had 6 fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. As of March 31, 2022, the annual installed production capacity of formulation facility in Valthera amounted to 522.64 million units, with an average dosage capability of 0.17 million tablets, 0.36 million capsules and 646.46 bottles of dry syrup per shift, which is defined as eight hours of production.

The Company is planning to raise capital from Public by issuing o 20,925,652 Equity Shares through Offer for Sale.

Concord Biotech Share Price

Concord Biotech share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Concord Biotech Market Cap

Market capitalization of Concord Biotech indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Concord Biotech is valued compared to its competitors.

Concord Biotech PE Ratio

Concord Biotech PE ratio helps investors understand what is the market value of each stock compared to Concord Biotech 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Concord Biotech PEG Ratio

The PEG ratio of Concord Biotech evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Concord Biotech ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Concord Biotech generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Concord Biotech ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Concord Biotech in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Concord Biotech Total Debt

Total debt of Concord Biotech shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Concord Biotech Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Concord Biotech compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Concord Biotech CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Concord Biotech over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Concord Biotech Technical Analysis

Technical analysis of Concord Biotech helps investors get an insight into when they can enter or exit the stock. Key components of Concord Biotech Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Concord Biotech shares often struggle to rise above due to selling pressure.

Concord Biotech Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Concord Biotech ’s financial health and profitability.

Concord Biotech Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Concord Biotech Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Concord Biotech Financials

The financials of Concord Biotech provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Concord Biotech Profit and Loss Statements

The profit and loss statement of Concord Biotech highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Concord Biotech .

Concord Biotech Balance Sheet

The balance sheet presents a snapshot of Concord Biotech ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Concord Biotech Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App